Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 35Other solid neoplasm 35Gynecologic 3Gastrointestinal 3Lymphoid 2Genitourinary 2Breast 2Sarcoma 1Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Sarcoma 35Osteosarcoma 22Central Nervous System Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Colorectal Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Neuroblastoma 4Gliosarcoma 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Astrocytoma 4Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Ependymoma 3Desmoplastic Small Round Cell Tumor 3Choroid Plexus Neoplasms 3Carcinoma, Ovarian Epithelial 3

Interventions

tislelizumab 2tazemetostat 2belinostat 2spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Sorafenib 1Rifampin 1Quality of Life 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1PM 01183 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1LY2940680 1Itraconazole 1Irinotecan 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Drug Therapy 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Cisplatin × Sarcoma × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡